Literature DB >> 33278107

Multisystem inflammatory syndrome in children.

Vijaya L Soma1, Gail F Shust1, Adam J Ratner1,2.   

Abstract

PURPOSE OF REVIEW: Here we summarize current knowledge about multisystem inflammatory syndrome in children (MIS-C), a presumed postinfectious inflammatory condition that has emerged as an important COVID-19-associated complication, to help clinicians identify and manage cases. RECENT
FINDINGS: Clinical presentation of MIS-C is dominated by significant inflammation. Fever, gastrointestinal symptoms, cardiac dysfunction, and hypotension are common features. Kawasaki disease-like findings are common, but epidemiologic data and recent mechanistic studies suggest that distinct inflammatory pathways mediate Kawasaki disease and MIS-C. A broad diagnostic approach is recommended, given overlapping presentations between MIS-C and many other disease processes. Current management of MIS-C is highly variable, depending on illness severity, and can range from supportive care to aggressive immune modulation. A multidisciplinary approach with early involvement of multiple pediatric subspecialists is recommended for complicated cases.
SUMMARY: Several studies have described the clinical manifestations of MIS-C, but definitive diagnosis remains challenging. Robust information about long-term outcomes awaits further study, as do immunologic data to refine diagnostic and therapeutic strategies.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33278107     DOI: 10.1097/MOP.0000000000000974

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  6 in total

Review 1.  Imaging findings in acute pediatric coronavirus disease 2019 (COVID-19) pneumonia and multisystem inflammatory syndrome in children (MIS-C).

Authors:  Jessica Kurian; Einat Blumfield; Terry L Levin; Mark C Liszewski
Journal:  Pediatr Radiol       Date:  2022-05-26

2.  Severe Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 in a 31-Year-Old Male Patient: The First Clinical Case Report From the Republic of Cyprus.

Authors:  Despina Markoulaki; Stelios Iordanou; Demetris Koukios; Ioanna Christoldoulou; Panos Papadopoulos; Chrystalla Timiliotou-Matsentidou
Journal:  Cureus       Date:  2022-02-26

Review 3.  Multisystem Inflammatory Syndrome in Neonates Born to Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review.

Authors:  Domenico Umberto De Rose; Flaminia Pugnaloni; Monica Calì; Sara Ronci; Stefano Caoci; Chiara Maddaloni; Ludovica Martini; Alessandra Santisi; Andrea Dotta; Cinzia Auriti
Journal:  Viruses       Date:  2022-04-02       Impact factor: 5.818

Review 4.  The role of cytokines and their antagonists in the treatment of COVID-19 patients.

Authors:  Zeinab Mohseni Afshar; Mohammad Barary; Arefeh Babazadeh; Ali Tavakoli Pirzaman; Rezvan Hosseinzadeh; Amirmasoud Alijanpour; Amirreza Allahgholipour; Seyed Rouhollah Miri; Terence T Sio; Mark J M Sullman; Kristin Carson-Chahhoud; Soheil Ebrahimpour
Journal:  Rev Med Virol       Date:  2022-05-27       Impact factor: 11.043

Review 5.  Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses.

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Mohammed A Garout; Ayman M Al-Qaaneh; Anupam A Sule; Raghavendra Tirupathi; Abbas Al Mutair; Saad Alhumaid; Abdulkarim Hasan; Manish Dhawan; Ruchi Tiwari; Khan Sharun; Ranjan K Mohapatra; Saikat Mitra; Talha Bin Emran; Muhammad Bilal; Rajendra Singh; Salem A Alyami; Mohammad Ali Moni; Kuldeep Dhama
Journal:  Pathogens       Date:  2021-05-07

6.  Systemic Inflammation and Microbial Translocation Are Characteristic Features of SARS-CoV-2-Related Multisystem Inflammatory Syndrome in Children.

Authors:  Nathella Pavan Kumar; Aishwarya Venkataraman; Luke Elizabeth Hanna; Sulochana Putlibai; M Karthick; Anuradha Rajamanikam; Kalaimaran Sadasivam; Balasubramanian Sundaram; Subash Babu
Journal:  Open Forum Infect Dis       Date:  2021-07-06       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.